600568.SH
ST中珠
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 2.16
−2.26%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 544.7M | 577.3M | 521.4M | 638.6M | 506.0M |
| Cost of Revenue | 455.2M | 473.8M | 454.8M | 477.5M | 378.5M |
| Gross Profit | 89.5M | 103.5M | 66.6M | 161.1M | 127.5M |
| Operating Expenses | |||||
| R&D Expense | 10.9M | 12.2M | 12.0M | 16.2M | 18.2M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 115.7M | 122.1M | 160.0M | 171.9M | 157.9M |
| Selling & Marketing Expense | 22.6M | 26.8M | 29.4M | 35.3M | 34.6M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 155.6M | 166.9M | 211.6M | 264.2M | 311.3M |
| Cost and Expenses | 610.8M | 640.7M | 666.5M | 741.7M | 689.8M |
| Operating Income (EBIT) | (125.5M) | (124.2M) | (628.6M) | (337.4M) | (778.4M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (126.4M) | (121.5M) | (627.3M) | (338.4M) | (801.3M) |
| Income Tax Expense | (8.7M) | (8.5M) | (2.1M) | 15.9K | (9.6M) |
| Bottom Line | |||||
| Net Income | (116.5M) | (114.2M) | (620.2M) | (343.9M) | (799.3M) |
| Earnings from Cont. Ops | (117.7M) | (112.9M) | (625.2M) | (338.4M) | (791.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (116.5M) | (114.2M) | (620.2M) | (343.9M) | (799.3M) |
| Per Share | |||||
| Basic EPS | (CN¥0.06) | (CN¥0.06) | (CN¥0.31) | (CN¥0.17) | (CN¥0.40) |
| Diluted EPS | (CN¥0.06) | (CN¥0.06) | (CN¥0.31) | (CN¥0.17) | (CN¥0.40) |
| Revenue Per Share | CN¥0.29 | CN¥0.30 | CN¥0.26 | CN¥0.32 | CN¥0.25 |
| Shares | |||||
| Basic Shares Outstanding | 1.9B | 1.9B | 2.0B | 2.0B | 2.0B |
| Diluted Shares Outstanding | 1.9B | 1.9B | 2.0B | 2.0B | 2.0B |
| Profitability Metrics | |||||
| EBITDA | — | (63.0M) | (562.1M) | (260.4M) | (694.3M) |
| D&A | — | 61.2M | 66.5M | 77.0M | 84.1M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026